Prosecution Insights
Last updated: April 19, 2026
Application No. 17/286,172

ADDITIVES TO STABILIZE POLYACRYLAMIDE CO-POLYMER SOLUTIONS UNDER HIGH SHEAR CONDITIONS

Final Rejection §103
Filed
Apr 16, 2021
Examiner
LENIHAN, JEFFREY S
Art Unit
1765
Tech Center
1700 — Chemical & Materials Engineering
Assignee
BASF Corporation
OA Round
7 (Final)
73%
Grant Probability
Favorable
8-9
OA Rounds
3y 1m
To Grant
90%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
665 granted / 910 resolved
+8.1% vs TC avg
Strong +17% interview lift
Without
With
+16.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
47 currently pending
Career history
957
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
43.2%
+3.2% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
28.2%
-11.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 910 resolved cases

Office Action

§103
DETAILED ACTION This Office Action is responsive to the amendment filed on 1/8/2026. The objections and rejections not addressed below are deemed withdrawn. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 103 Claims 1-5, 7, and 9-16 are rejected under 35 U.S.C. 103 as being unpatentable over Bennis et al, US2019/0343987 (of record). Bennis discloses a lubricious coating composition comprising a copolymer of sodium acrylate and acrylamide, corresponding to the claimed acrylamide copolymer (A) (for claims 1, 15, 16); a high molecular weight polyvinylpyrrolidone, corresponding to additive (B)(iii) (for claims 1, 15, 16); a low molecular weight polyvinylpyrrolidone, also corresponding to additive (B)(iii) (for claims 1, 15, 16); and a solvent comprising water, corresponding to claimed component (C) (for claims 1, 15, 16) (¶0013-0014, 0071). Bennis further teaches the inclusion of antimicrobial agents (¶0080), corresponding to the claimed agrochemical which is a pesticide (for claims 1, 7, 15, 16). The prior art composition is prepared by combining the components with one another (for claims 10, 11, 13) (¶0071). Regarding the requirement that the acrylamide copolymer (A) is hydrated: The prior art discloses a composition wherein an acrylamide copolymer is combined with water; it is therefore reasonably expected that the acrylamide copolymer of the composition of Bennis is hydrated (for claims 1, 15, 16). Regarding the amount of additive: Bennet teaches the prior art composition may contain as little as 1 wt% solids which comprise the high and low molecular weight polyvinylpyrrolidones, the acrylate/acrylamide copolymer, and the crosslinking agent (¶0072). The solids may in turn contain as much as 50 wt% of the acrylate/acrylamide copolymer (¶0061). The sum of the amounts of the high and low molecular weight polyvinylpyrrolidones and the crosslinking agent therefore can be as little as 50 wt% of the solids. Given that the solids can be as little as 1 wt% of the overall composition, an ordinary artisan can therefore calculate that the sum of the amounts of the high and low molecular weight polyvinylpyrrolidones and the crosslinking agent can be as low as 0.5 wt% of the overall composition. Furthermore, the ratio of total amount of polyvinylpyrrolidones to crosslinking agent may be as low as 0.5:1 (¶0066). Given this ratio, an ordinary artisan can calculate that if the sum of the amount of crosslinking agent (x) and the total amount of polyvinylpyrrolidones (0.5x) is 0.5 wt% of the overall composition (i.e., x + 0.5x = 0.5), an ordinary artisan can calculate that the prior art reads on a composition wherein the overall composition has a crosslinking agent content (x) of about 0.33 wt% and the total amount of polyvinylpyrrolidones is about 0.17 wt%. Finally, Bennis teaches that the weight ratio of high molecular weight polyvinylpyrrolidone to low molecular weight polyvinylpyrrolidone may be 90:10 (¶0058). Given that 1) the overall coating composition can contain as little as 0.33 wt% total of polyvinylpyrrolidones and 2) that the amount of low molecular weight polyvinylpyrrolidone may be as low as 10% of the total amount of polyvinylpyrrolidones, it is calculated that the low molecular weight polyvinylpyrrolidone may be present in the prior art coating composition in an amount as low as about 0.033 wt%, overlapping the claimed range (for claims 1, 15, 16). Regarding claims 2-4: The instant claims depend from claim 1 and recite additional limitations regarding recited additive (B)(i) (claim 2) or additive (B)(ii) (claims 3,4). Note, however, that the claims do not contain any language requiring the additive to be either (B)(i) or (B)(ii). The prior art composition therefore corresponds to the claimed invention when the additive is species (B)(iii). Regarding claim 5: Bennis defines the low molecular weight polyvinylpyrrolidone as having a molecular weight in the range of 2000 to 95000 (¶0055); note that this range is entirely encompassed by the claimed range. Regarding claim 9: As noted above, both the high molecular weight polyvinylpyrrolidone and the low molecular weight polyvinylpyrrolidone of the prior art composition fall within the scope of claimed additive (B)(iii). The prior art composition therefore comprises more than one additive (B) as required. Bennis does not particularly point to a process comprising the steps of combining recited components (A), (B), and (C) to form a composition, followed by combining said composition with an aqueous solution of acrylamide (co)polymer or a composition having at least one additive in an amount of 0.01 to 0.05 wt%. It has been held that in the case where the claimed ranges overlap or lie inside ranges disclosed in the prior art, a prima facie case of obviousness exists; see In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages; see In re Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 (" (MPEP § 2144.05). As discussed above, the prior art teaches the production of a composition which can comprise low molecular weight polyvinylpyrrolidone in an amount as low as 0.033 wt%, overlapping the claimed range. Barring a showing of evidence demonstrating unexpected results, it therefore would have been obvious to prepare a composition wherein the low molecular weight polyvinylpyrrolidone is present in an amount in the claimed range (for claims 1, 15, 16). Regarding the claimed process (for claims 11, 12): As discussed earlier in this Action, Bennis discloses a composition comprising the same components as the product obtained from the recited process. Barring a showing of evidence demonstrating unexpected results, it therefore would have been obvious to modify the teachings of Bennis by combining the ingredients in the required order, with the reasonable expectation of obtaining a final aqueous composition suitable for use as a lubricious coating. Regarding the claimed reduced shear effects (for claim 10), rate of droplet size distribution change (for claim 12), stabilization of the interaction of the long strands of the polyacrylamide (for claim 13) and slower rate of droplet size distribution increase (for claim 14): “[T]he PTO can require an applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his [or her] claimed product. Whether the rejection is based on inherency under 35 U.S.C. 102, on prima facie obviousness under 35 U.S.C. 103, jointly or alternatively, the burden of proof is the same…" as that required with respect to product-by-process claims. In re Fitzgerald, 619 F.2d 67, 70, 205 USPQ 594, 596 (CCPA 1980) (MPEP § 2112). The burden is therefore shifted to the applicant to prove that the properties used to define the interpolymers of the instant application would not be present in the block copolymers disclosed by Turner. As discussed in the previous paragraphs, Bennis renders obvious a composition comprising the same components in the same amounts as used to define the claimed invention. As the composition rendered obvious by the prior art appears to be identical to the claimed composition, it is reasonably expected that its properties would be the same as those of the claimed invention. The burden is therefore shifted to the applicant to provide evidence that the properties used to define the claimed invention would not be present in the prior art. Response to Arguments Applicant's arguments filed 1/8/2026 have been fully considered but they are not persuasive. Applicant argues that Bennis does not teach the claimed composition comprising an agrochemical, stating that the prior art composition comprises a therapeutic agent for use in treating the human body instead. In response, applicant’s specification teaches that the term agrochemical reads on the use of pesticides (specification ¶0003), and that the term “pesticide” in turn includes compounds having antibacterial activity (see specification ¶0005) and fungicides (specification ¶0003). Bennis specifically teaches that the prior art composition may comprise antibiotic agents (¶0080); the term “antibiotic” refers to compounds that kill bacteria or inhibit their growth. Furthermore, Bennis teaches that the prior art composition may comprise antimicrobial agents (¶0080); the term “antimicrobial” is used to broadly refer to compounds that kill or inhibit the growth of microorganisms including bacteria, viruses, and fungi. Bennis therefore teaches the inclusion of antibiotics and/or antimicrobial agents that perform the function(s) disclosed in applicant’s specification for the claimed agrochemical. In response to applicant's argument that the prior art is directed towards a different use, a recitation of the intended use must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. As discussed in the previous paragraph, Bennis discloses the inclusion of antibiotic and/or antimicrobial agents that are capable of performing the same function-i.e., killing or inhibiting the growth of microbes such as bacteria and fungi- as the claimed agrochemical. The burden is therefore shifted to applicant to provide evidence that the prior art compounds would not be capable of performing this function. To the extent that applicant argues that Bennis is directed towards a different field than the disclosed invention, it is noted that the features upon which applicant relies (i.e., work in an agricultural area) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). As written, the claimed invention is merely a composition comprising the recited components and a method of making said composition. The claimed invention do not recite any steps requiring that the composition be used in a specific manner. The rejection is therefore maintained. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEFFREY S LENIHAN whose telephone number is (571)270-5452. The examiner can normally be reached Mon.-Fri. 5:30-2:00PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Riviere Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEFFREY S LENIHAN/Primary Examiner, Art Unit 1765
Read full office action

Prosecution Timeline

Apr 16, 2021
Application Filed
Oct 05, 2023
Non-Final Rejection — §103
Dec 06, 2023
Response Filed
Dec 11, 2023
Final Rejection — §103
Jan 25, 2024
Response after Non-Final Action
Mar 06, 2024
Request for Continued Examination
Mar 07, 2024
Response after Non-Final Action
Mar 20, 2024
Non-Final Rejection — §103
Jun 06, 2024
Response Filed
Oct 02, 2024
Final Rejection — §103
Feb 10, 2025
Request for Continued Examination
Feb 11, 2025
Response after Non-Final Action
Mar 22, 2025
Non-Final Rejection — §103
May 30, 2025
Response Filed
Sep 05, 2025
Non-Final Rejection — §103
Jan 08, 2026
Response Filed
Mar 06, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600810
PROCESS FOR PREPARING OLEFIN-ACRYLATE BLOCK COPOLYMERS
2y 5m to grant Granted Apr 14, 2026
Patent 12590223
METHOD FOR PREPARING METALLOPOLYMER-BASED COATING SOLUTION
2y 5m to grant Granted Mar 31, 2026
Patent 12577425
ANTIBACTERIAL POLYMER COMPOSITION COMPRISING POLYMER COMPOUND OBTAINED BY GRAFT POLYMERIZING CATIONIC MONOMER AND FLUORINE-BASED ACRYLIC MONOMER TO FLUORINE-BASED COPOLYMER
2y 5m to grant Granted Mar 17, 2026
Patent 12577342
Acrylic Emulsions Modified with Functional (Meth)acrylates to Enable Crosslinking
2y 5m to grant Granted Mar 17, 2026
Patent 12540242
EPOXY RESIN COMPOSITION, CURED PRODUCT, AND ELECTRICAL OR ELECTRONIC COMPONENT
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

8-9
Expected OA Rounds
73%
Grant Probability
90%
With Interview (+16.8%)
3y 1m
Median Time to Grant
High
PTA Risk
Based on 910 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month